MilliporeSigma
  • Home
  • Search Results
  • Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials.

Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials.

Trends in pharmacological sciences (2011-09-29)
Martina Lukasova, Julien Hanson, Sorin Tunaru, Stefan Offermanns
ABSTRACT

Nicotinic acid (niacin) has been used for decades to prevent and treat atherosclerosis. The well-documented antiatherogenic activity is believed to result from its antidyslipidemic effects, which are accompanied by unwanted effects, especially a flush. There has been renewed interest in nicotinic acid owing to the need for improved prevention of atherosclerosis in patients already taking statins. In addition, the identification of a nicotinic acid receptor expressed in adipocytes and immune cells has helped to elucidate the mechanisms underlying the antiatherosclerotic as well as the unwanted effects of this drug. Nicotinic acid exerts its antiatherosclerotic effects at least in part independently of its antidyslipidemic effects through mechanisms involving its receptor on immune cells as well as through direct and indirect effects on the vascular endothelium. Here, we review recent data on the pharmacological effects of nicotinic acid and discuss how they might be harnessed to treat other inflammatory diseases such as multiple sclerosis or psoriasis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Nicotinic acid, ≥98%
Sigma-Aldrich
Nicotinic acid, meets USP testing specifications
Sigma-Aldrich
Nicotinic acid, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
Nicotinic acid, ≥99.5% (HPLC)
Supelco
Nicotinic acid, analytical standard
Supelco
Niacin (Nicotinic Acid), Pharmaceutical Secondary Standard; Certified Reference Material
USP
Niacin, United States Pharmacopeia (USP) Reference Standard
Nicotinic acid, European Pharmacopoeia (EP) Reference Standard